The process of wound healing relies heavily on the continual viability of healthy tissues and the prevention of bacterial infection. Dermacyn™ wound care solution, featuring a patented Microcyn technology, stands out as a super-oxidised disinfectant solution designed to address ulcers, wounds, cuts and burns. This research undertook an assessment of the cytotoxicity and antimicrobial effectiveness of commercially available Dermacyn™ with varying shelf lives through in vitro assays. Three different Dermacyn™ products, each with distinct shelf lives, were utilised and subjected to testing. The assessment of cytotoxicity was executed on the Medical Research Council cell strain 5 (MRC-5) cell line using flow cytometry alongside LIVE/DEAD cell viability assays. Simultaneously, the antimicrobial efficacy against wound pathogens was evaluated through the suspension test plate count method. The findings revealed that the products exhibited remarkably low cytotoxicity, registering less than 1% of cell death on MRC-5 cells. Moreover, they exhibited significant antimicrobial efficacy, achieving a notable 3-log reduction in colony-forming units (CFU) following a five-minute exposure to 20 challenge strains. Nevertheless, it was observed that both cytotoxicity and antimicrobial efficacy experienced a decline as the product approached its expiry date. In conclusion, Dermacyn™ wound care solution emerges as a remarkably safe option for human cells, boasting a high level of antimicrobial efficacy. It effectively met the fundamental requirements for wound care solutions and management, providing a promising avenue for promoting optimal healing conditions.
Evaluation of the Antimicrobial Effectiveness and Cytotoxicity of Wound Care Solutio
Author
Abstrak
Proses penyembuhan luka bergantung pada sel tisu yang sihat dan bebas daripada jangkitan bakteria. Produk larutan rawatan luka Dermacyn™ yang dihasilkan dengan teknologi Microcyn berpaten, adalah larutan super-oksida yang digunakan untuk menyembuh ulser, luka potongan dan luka lecur. Penyelidikan ini dijalankan untuk menguji sitotoksisiti dan keberkesanan antimikrob Dermacyn™ yang dijual secara komersial dengan tarikh luput yang berbeza melalui ujian in-vitro. Tiga produk Dermacyn™ dengan tarikh luput yang berbeza diuji dalam penyelidikan ini. Penilaian sitotoksisitas dijalankan diatas sel Medical Research Council 5 (MRC-5). Selepas sel dirawati oleh produk, peratusan sel dikira dengan kit Cell Viability LIVE/DEAD bersama flow cytometry. Selain daripada itu, keberkesanan antimikrob terhadap patogen luka juga diuji melalui kaedah (suspension test plate count). Penemuan menunjukkan bahawa produk menunjukkan sitotoksisiti yang rendah, dan hanya menunjukkan kurang daripada 1% kematian sel pada sel MRC-5 selepas rawatan produk. Selain daripada itu, produk ini juga menunjukkan keberkesanan antimikrob yang signifikan, dengan mencapai pengurangan log 3 'colony-forming units' (CFU) setelah didedahkan selama lima minit kepada 20 jenis bakteria yang diuji. Walau bagaimanapun, kedua-dua sitotoksisiti dan keberkesanan antimikrob mengalami penurunan apabila produk mendekati tarikh luputnya. Kesimpulannya, produk Dermacyn™ adalah pilihan yang selamat untuk sel manusia, dan memberi keberkesanan antimikrob yang tinggi. Ia memenuhi keperluan asas untuk pengurusan luka dan menggalakkan penyembuhan luka secara optimum.
Kata kunci
Abstract
|
|
Related Images
